Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • How to Manage…
  • Published:

How to Manage…

How to manage children and young adults with myeloproliferative neoplasms

Leukemia volume 26, pages 1452–1457 (2012)Cite this article

Subjects

Abstract

On the basis of my personal clinical and research experience and validated by the current literature, my approach to the management of pediatric (age <18 years) and young patients (age <40 years) with classic myeloproliferative neoplasms is presented by focusing on diagnosis, patient communication, risk stratification and therapy. The WHO-2008 diagnostic criteria are recommended, even though in children suspected with essential thrombocythemia (ET), a specific set of diagnostic features may be required. Patient communication includes information on natural history, genetic abnormalities and counseling in all women of child-bearing age. The main challenge in children and young adults with ET and polycythemia vera (PV) is to avoid recurrence of major thrombosis by selecting those patients who ultimately can benefit from cytotoxic and antithrombotic therapy without increasing the incidence of drug-induced side effects. In asymptomatic low-risk patients no therapy is prescribed while in high-risk low-dose aspirin, hydroxyurea and interferon-alpha are my first line drugs. My first decision when considering treatment of a young patient with primary myelofibrosis (PMF) or post-PV or post ET-myelofibrosis, is whether he/she qualifies for bone marrow allotransplantation. In the remaining young PMF patients palliative therapy or experimental drugs are considered.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Campbell PJ, Green AR . The myeloproliferative disorders. N Engl J Med 2006; 355: 2452–2466.

    Article  CAS  Google Scholar 

  2. Tefferi A, Vainchenker W . Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29: 573–582.

    Article  CAS  Google Scholar 

  3. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097.

    Article  CAS  Google Scholar 

  4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  Google Scholar 

  5. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007; 110: 3384–3386.

    Article  CAS  Google Scholar 

  6. Gassas A, Doyle JJ, Weitzman S, Freedman MH, Hitzler JK, Sharathkumar A et al. A basic classification and a comprehensive examination of pediatric myeloproliferative syndromes. J Pediatr Hematol Oncol 2005; 27: 192–196.

    Article  Google Scholar 

  7. Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O et al. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. Pediatr Blood Cancer 2008; 51: 802–805.

    Article  Google Scholar 

  8. Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179–3184.

    Article  Google Scholar 

  9. Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.

    Article  CAS  Google Scholar 

  10. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson C et al. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol 2009; 82: 255–259.

    Article  Google Scholar 

  11. Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood 2009; 113: 4171–4178.

    Article  CAS  Google Scholar 

  12. Mallouh AA, Sa'di AR . Agnogenic myeloid metaplasia in children. Am J Dis Child 1992; 146: 965–967.

    CAS  PubMed  Google Scholar 

  13. Bonduel M, Sciuccati G, Torres AF, Pierini A, Gallo G . Familial idiopathic myelofibrosis and multiple hemangiomas. Am J Hematol 1998; 59: 175–177.

    Article  CAS  Google Scholar 

  14. Kvasnicka HM, Thiele J . The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 2006; 32: 362–371.

    Article  Google Scholar 

  15. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895–2901.

    Article  CAS  Google Scholar 

  16. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M . Increased risks of PV, ET, and PMF among 24 577 first-degree relatives of 11 039 patients with MPNs in Sweden. Blood 2008; 112: 2199–2204.

    Article  CAS  Google Scholar 

  17. Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007; 25: 5630–5635.

    Article  Google Scholar 

  18. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770.

    Article  Google Scholar 

  19. Pardanani A, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, Hanson CA et al. The JAK2 46/1 haplotype confers susceptibility to ET regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia 2010; 24: 110–114.

    Article  CAS  Google Scholar 

  20. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115: 778–782.

    Article  CAS  Google Scholar 

  21. Harrison C . Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol 2005; 129: 293–306.

    Article  CAS  Google Scholar 

  22. Barbui T, Finazzi G . Myeloproliferative disease in pregnancy and other management issues. Hematol Am Soc Hematol Educ Program 2006, 246–252.

    Article  Google Scholar 

  23. Gangat N, Wolanskyj AP, Schwager SM, Mesa RA, Tefferi A . Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer 2006; 106: 2406–2411.

    Article  CAS  Google Scholar 

  24. Danish EH, Rasch CA, Harris JW . Polycythemia vera in childhood: case report and review of the literature. Am J Hematol 1980; 9: 421–428.

    Article  CAS  Google Scholar 

  25. Cario H, McMullin MF, Pahl HL . Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol 2009; 88: 713–719.

    Article  Google Scholar 

  26. Mitus AJ, Barbui T, Shulman LN, Rosenthal DS, Viero P, Cortelazzo S et al. Hemostatic complications in young patients with essential thrombocythemia. Am J Med 1990; 88: 371–375.

    Article  CAS  Google Scholar 

  27. Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149: 352–375.

    Article  CAS  Google Scholar 

  28. Barosi G, Birgegard G, Finazzi G Griesshammer M, Harrison C, Hasselbalch HC et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 2009; 113: 4829–4833.

    Article  CAS  Google Scholar 

  29. van Genderen PJJ, Budde A, Michiels JJ, van Strik R, van Vliet HH . The reduction of large von Willebrand factor multimers in plasma in essential thrombocythemia is related to the platelet count. Br J Haematol 1996; 93: 962–965.

    Article  CAS  Google Scholar 

  30. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T . Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 2003; 101: 3749.

    Article  CAS  Google Scholar 

  31. Sekhar M, Prentice HG, Popat U, Anderson D, Janmohammed R, Roberts I et al. Idiopathic myelofibrosis in children. Br J Haematol 1996; 93: 394–397.

    Article  CAS  Google Scholar 

  32. Boxer LA, Camitta BM, Berenberg W, Fanning JP . Myelofibrosis-myeloid metaplasia in childhood. Pediatrics 1975; 55: 861–865.

    CAS  PubMed  Google Scholar 

  33. Naithani R, Tyagi S, Choudhry VP . Secondary myelofibrosis in children. J Pediatr Hematol Oncol 2008; 30: 196–198.

    Article  Google Scholar 

  34. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR . Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132–143.

    CAS  PubMed  Google Scholar 

  35. Najean Y, Rain JD . The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981. Semin Hematol 1997; 34: 6–16.

    CAS  PubMed  Google Scholar 

  36. Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R . The haematocrit and platelet target in polycythemia vera. Br J Haematol 2007; 136: 249–259.

    Article  Google Scholar 

  37. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114–124.

    Article  CAS  Google Scholar 

  38. Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116: 1205–1210.

    Article  CAS  Google Scholar 

  39. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008-WHO-criteria. Leukemia 2011 (in press).

  40. Tefferi A, Gangat N, Wolanskyj AP . Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia: does number matter? Blood 2006; 108: 2493–2494.

    Article  CAS  Google Scholar 

  41. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK2 mutation status. Blood 2007; 109: 2310–2313.

    Article  CAS  Google Scholar 

  42. Passamonti F, Malabarba L, Orlandi E, Baratè C, Canevari A, Brusamolino E et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003; 88: 13–18.

    PubMed  Google Scholar 

  43. Ruggeri M, Finotto S, Fortuna S, Rodeghiero F . Treatment outcome in a cohort of young patients with polycythemia vera. Intern Emerg Med 2010; 5: 411–413.

    Article  Google Scholar 

  44. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224–2232.

    Article  Google Scholar 

  45. Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218–1223.

    Article  Google Scholar 

  46. Palandri F, Polverelli N, Ottaviani E, Castagnetti F, Baccarani M, Vianelli N . Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. Haematologica 2010; 95: 1038–1040.

    Article  Google Scholar 

  47. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372–380.

    Article  CAS  Google Scholar 

  48. Carobbio A, Finazzi G, Antonioli E, Vannucchi AM, Barosi G, Ruggeri M et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. Blood 2010; 116: 1051–1055.

    Article  CAS  Google Scholar 

  49. Bjorkholm J, Derolf AR, Ekstrand C, Kristinsson SY, Ekstrand C, Goldin LR et al. Clinical risk for AML/MDS transformation in Philadelphia negative chronic myeloproliferative neoplasms. A population-based nested case-control study in Sweden. J Clin Oncol 2011; 29: 2410–2415.

    Article  Google Scholar 

  50. Kiladjian JJ, Chevret S, Dosquet C, Fenaux P, Chomienne C, Rain J-D . Long-term outcome in polycythemia vera: final analysis of a randomized trial comparing hydroxyurea (HU) to pipobroman (Pi). Blood 2008; 112 (abstract 1746).

  51. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T . Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110: 577–583.

    Article  CAS  Google Scholar 

  52. Antonioli A, Guglielemelli P, Pieri L, Finazzi MC, Rumi E, Martinelli V et al. Side effects of hydroxyurea in classic chronic myeloproliferative neoplasms. A retrospective study of 3411 patients. Haematologica 2011; 96 (suppl 2): 380 (abstract 913).

    Google Scholar 

  53. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon alpha-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065–3072.

    Article  CAS  Google Scholar 

  54. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S et al. Pegylated interferon alpha-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009; 27: 5418–5424.

    Article  CAS  Google Scholar 

  55. Hasselbalch HC, Kiladjian JJ, Silver RT . Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J Clin Oncol 2011; 29: e564–e565.

    Article  Google Scholar 

  56. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 2007; 21: 277–280.

    Article  CAS  Google Scholar 

  57. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33–45.

    Article  CAS  Google Scholar 

  58. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relation to therapy. J Clin Oncol 2009; 27: 2991–2999.

    Article  CAS  Google Scholar 

  59. Murphy S, Peterson P, Iland H, Laszlo J . Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39.

    CAS  PubMed  Google Scholar 

  60. Thiele J, Kvasnicka HM, Vardiman JW, Orazi A, Franco V, Gisslinger H et al. Bone marrow fibrosis and diagnosis of essential thrombocythemia. J Clin Oncol 2009; 27: e220–e221.

    Article  Google Scholar 

  61. Gisslinger H, Gotic M, Holowiecki J, Miroslav P, Juergen T, Hans MK et al. Final results of the ANAHYDRET study: non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed WHO essential thrombocythemia patients. Blood 2008; 112 (abstract 661).

  62. Tefferi A . Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplant 2010; 45: 419–421.

    Article  CAS  Google Scholar 

  63. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117–1127.

    Article  CAS  Google Scholar 

  64. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789–796.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology and Research Foundation, Ospedali Riuniti di Bergamo, Bergamo, Italy

    T Barbui

Authors
  1. T Barbui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Barbui.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barbui, T. How to manage children and young adults with myeloproliferative neoplasms. Leukemia 26, 1452–1457 (2012). https://doi.org/10.1038/leu.2012.12

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.12

Keywords

This article is cited by

Search

Advanced search

Quick links